TRANSITIONAL CELL CARCINOMA METASTATIC

This adverse event was reported 117 times

TRANSITIONAL CELL CARCINOMA METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 INTERLEUKIN-12 HUMAN RECOMBINANT 1 0.0909
1 ENFORTUMAB VEDOTIN 41 0.0052
2 LUMASIRAN 1 0.0026
3 AVELUMAB 8 0.0020
4 ERDAFITINIB 1 0.0008
5 PEMBROLIZUMAB 55 0.0005
6 BASILIXIMAB 6 0.0005
7 SODIUM FERRIC GLUCONATE COMPLEX 1 0.0005
8 NERATINIB 1 0.0004
9 EVEROLIMUS TABLETS 6 0.0004
See all drugs enriched for association with TRANSITIONAL CELL CARCINOMA METASTATIC